Formoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling

dc.contributor.authorChutima Kaewpiboon
dc.contributor.authorNawong Boonnak
dc.contributor.authorSirichat Kaowinn
dc.contributor.authorNatpaphan Yawut
dc.contributor.authorYoung‐Hwa Chung
dc.date.accessioned2026-05-08T19:20:43Z
dc.date.issued2022-6-30
dc.description.abstract, at a non-cytotoxic concentration reduced the expression of the signal transducer and activator of transcription 1 (STAT1) and histone deacetylase 4 (HDAC4) proteins, leading to inhibition of CSC-like phenotypes such as cell migration, invasion, and sphere-forming ability. Moreover, we found that treatment with STAT1 or HDAC4 small interfering RNAs significantly hindered these CSC-like phenotypes, indicating that STAT1 and HDAC4 play a role in the malignant tumor features. Taken together, our findings suggest that XanX may be a potential new therapeutic agent targeting malignant lung tumors.
dc.identifier.doi10.15430/jcp.2022.27.2.112
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/17683
dc.publisherJournal of Cancer Prevention
dc.subjectHistone Deacetylase Inhibitors Research
dc.subjectNatural Compound Pharmacology Studies
dc.subjectGenomics, phytochemicals, and oxidative stress
dc.titleFormoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling
dc.typeArticle

Files

Collections